

Anti Cancer Drugs

By - Dr. Shikha Sharma (NEETPG Squad, FitDocMed)

- NEETPG
- INICET
- FMGE

Join FitDocMed Courses at
www.fitdocmed.com


Cell cycle effects of anticancers

G₁- Etoposide

S - Antimetabolites: Methotrexate, GMP, 5FU, Cladribine, Capecitabine

G₂ - Topoisomerase θ: Irinotecan, Topotecan, Etoposide & Bleomycin.

M - Vinca alkaloids: Vincristine, vinblastine, venorelbine. Taxanes: Paclitaxel, Docetaxel, Cabazitaxel. Erbitux, Eramustine, Ixabepilone.



Alkylating Agents

cell cycle non specific - Alkylate nucleophilic groups on DNA bases [N₇ of guanine] → causing crosslinking + abnormal base pairing & DNA strand breakage.

MC ADRS - GI distress, bone marrow suppression, alopecia, 2^o leukemias & sterility.

Nitrogen Mustards Cyclophosphamide - Hepatic biotransformation. Degradation product acrolein → Hemorrhagic cystitis. ↓ by vigorous hydration & mesna. Also causes cardiac dysfunction, pulmonary toxicity & SIADH. DOC → Wegeners granulomatosis.

Ilosfamide - Acrolein & chloracetaldehyde → Hemorrhagic cystitis ↑ & nephrotoxicity.
↑ Rlo neurotoxicity also.

Mechlorethamine - Hodgkins disease. Powerful vesicant.

Melphalan - Multiple myeloma.

Nitrosoureas Carmustine, lomustine, semustine → lipid soluble cross BBB, thus used for brain tumors like gliomas ↑ Delayed sustained neutropenia

Dacarbazine - 1^o action on RNA & protein synthesis.

Streptozocine - Destroys β cell of pancreas. Used for islet cell tumors. Minimum bone marrow toxicity.

Busulfan - Adrenal insufficiency, pulmonary fibrosis [sinusoidal obstruction syndrome], skin hyperpigmentation & hyperuricemia.

Procarbazine - Most leukemogenic, disulfiram like reaction \in alcohol, hypnosis, dreams.

Chlorambucil - Spares myelocytes, used for CLL.

Platinum Compounds

Cisplatin, carboplatin, oxaliplatin \rightarrow use platinum to cross link DNA \rightarrow dimers & breakage.

Nausea & vomiting maximum compared to all anticancer drugs

Nephrotoxicity, ototoxicity & neurotoxicity. Maximum nephrotoxicity \rightarrow cisplatin & maximum hematotoxicity / BM suppression \rightarrow carboplatin.

Oxaliplatin effective against drugs resistant to cisplatin / carboplatin $\uparrow\uparrow$ Neurotoxicity

Chloride diuresis prior to cisplatin therapy \rightarrow \downarrow Renal toxicity, no effect on ototoxicity.

Slow IV infusion Inactivated by aluminium thus not used simultaneously.

Amitostine - \downarrow cisplatin induced nephrotoxicity & xerostomia.

\downarrow all serum ions \rightarrow hypomagnesemia, hypokalemia, hypocalcemia, hypophosphatemia

Always development of AML \in >4 yrs of treatment.

Anti-metabolites

Sphase action \rightarrow \ominus dividing cells. Immunosuppressive properties also.

Folic Acid analogues Methotrexate, pemetrexed, pralatrexate \rightarrow \ominus dihydrofolate reductase [DHFRase] & thymidylate synthase.

Methotrexate - sequestered in 3rd space \rightarrow prolonged immunosuppression. Vigorously hydrate to \ominus renal crystallisation

ADRs \rightarrow Bone marrow suppression & mucositis. \downarrow Toxicity to normal cells \rightarrow co administer leucovorin, folinic acid, citrovorum factor. [Leucovorin rescue]. Doesn't \ominus neurotoxicity
Alkalisation of urine also \downarrow toxicity.

Glucarpidase \rightarrow MTX cleaving enzyme. \uparrow Toxicity \in NC AIDS. It \downarrow renal excretion

Long term use \rightarrow Hepatotoxicity, pulmonary infiltrates & fibrosis

I - Inhibit - Immunosuppressant

C - Crohns disease

A - Abortions

N - Non Hodgkins lymphoma

C - choriocarcinoma [DOC]

E - Ectopic pregnancy

R - Rheumatoid arthritis & psoriasis

} Uses of methotrexate

Pemetrexed - Approved for mesothelioma treatment folic acid & vit. B12 ↑ toxicity w/o interfering in clinical actions

Pralatrexate - Peripheral T cell lymphoma.

Purine Analogs GMP & GTG → Activated by HGPRTase → ⊖ several enzymes in purine synthesis. Metabolised by xanthine oxidase → When given in allopurinol [xanthine oxidase ⊖] ↓ dose of GMP & azathioprine to 1/4 th.

Treatment of acute & chronic leukemias.

Dose limiting bone marrow suppression & hepatotoxicity

Cladribine - Resistant to degradation by adenosine deaminase. DOC: hairy cell leukemia

Fudarabine - DOC: CLL. Used along in pentostatin may cause severe pulmonary toxicity. Immunosuppression on long term use → All patient are given cotrimoxazole prophylaxis for pneumocystis in purine analogs.

Pyrimidine Analogs Cytarabine - most effective for induction of remission in AML.

Activated by kinases → CTP arabinoside → ⊖ DNA polymerase

High dose → Neurotoxicity, cerebellar toxicity [ataxia, peripheral neuropathy]

SFU - converted to 5' dUMP → OTS. Converted to CO₂ & eliminated via lungs. Oral prodrug → capecitabine → hyperbilirubinemia.

SFU/capecitabine → single strand breaks → ⊖ DNA & RNA

ADRs: Hand & foot syndrome [erythromelalgia & tingling, numbness, pain, erythema, swelling & ↑ pigmentation]. ↑ by uridine triacetate.

Gemcitabine - Potent radiosensitiser. DOC for pancreatic cancers.

S'Azacytidine - DNA hypomethylation. DOC myelodysplasia

Mitotic spindle ⊖

Vinca Alkaloids Vincristine, vinblastine & vinorelbine → ⊖ polymerisation of microtubules thus ⊖ mitotic spindle formation. M phase specific.

Vinblastine - Metastatic testicular tumors. Bone marrow suppression & SIADH.

Vincristine - ↓ glucocorticoids for remission of childhood leukemias [DOC] Pediatric solid tumors [Wilms, neuroblastoma, rhabdomyosarcoma] & lymphomas. Marrow sparing but neurotoxic [peripheral neurotoxicity] & SIADH

Taxanes Paclitaxel, docetaxel → interfere ⊖ mitotic spindles → ⊖ disassembly of the microtubules. Paclitaxel causes hypersensitivity reaction, ↑ by protein binding. Both cause bone marrow suppression & neurotoxicity.

cabazitaxel → Microtubule ⊖ used ⊖ prednisone for hormone refractory metastatic prostate carcinoma.

Ixabepilone - Advanced breast cancer, given in combination ⊖ capecitabine. Binding to tubulin ⊕ microtubule stabilisation → arrest cell in G₂ M.

Erbulin mesylate - Microtubule ⊖ for metastatic breast cancer & liposarcoma

Estramustine - Estrogen + mechlorethamine used for prostatic cancer. Anti-mitogenic drug by binding to tubulin. Estrogenic side → Gynecomastia & impotence.

Topoisomerase ⊖

Camptothecins - Irinotecan & topotecan → ⊖ topoisomerase I [nicks, introduces -ve supercoils & reseals DNA strand].

Topotecan - Advanced ovarian cancer. Dose limiting neuropathy



Inirotecan - prodrug, converted in liver to active metabolite & eliminated in bile. ↓ dose in hepatic failure. Dose for advanced colorectal cancer = 5FU. Dose limiting diarrhoea. Myelosuppression & cholinergic syndrome.

Etopodophyllotoxins Etoposide & teniposide → ⊖ topoisomerase II → DNA strand breaks. Act at late S & early G₂ phase. GI distress & myelosuppression.

Etoposide - testicular, prostate & oat cell carcinoma of lung. Results in ALL within 1-3y. Absent myelodysplastic period preceding AML. High dose hepatotoxic.

Antitumor Antibiotics

Anthracycline antibiotics → CCNS except bleomycin [G₂] ⊖ Topoisomerase II.

Doxorubicin, daunorubicin - acute leukemias

Idarubicin, epirubicin - solid tumors [breast carcinoma, Ewings & soft tissue sarcoma]

Generate semiquinone free radicals → cardiotoxicity [dilated cardiomyopathy & heart failure]. ↓ α-tocopherol & dexamethasone [free radical scavenger]. Dose dependent effect maybe present after stopping drug. Earliest morphological feature = swelling of ER fib myofibrillar dropout.

Red coloured urine & radiation recall reaction [erythema & desquamation of skin at sites of previous radiation exposure]


Mitoxantrone - ↓ cardiotoxic. AML, advance hormone resistant prostate cancer & late stage, 2° progressive multiple sclerosis.

Valrubicin - Intravesicle therapy of BCG refractory urinary bladder carcinoma in situ.

Dactinomycin - ⊖ DNA dependent RNA synthesis. Used for solid tumors in children [Wilms tumor & rhabdomyosarcoma] & choriocarcinoma. Radiosensitiser.

Bleomycin - G₂ ⊖ DNA strand breaks & free radical formation. Cutaneous toxicity [ulcers, hyperpigmentation, hyperkeratosis, erythema]. Pulmonary fibrosis, hypersensitivity & mucocutaneous reaction. Earliest indicator of ADR → ↓ leuc. [Type 1 pneumocyte necrosis = type 2 pneumocyte hyperplasia].

Mitomycin - Alkylating agent. Intravesical therapy to treat superficial bladder cancers & anal carcinoma [\pm radiotherapy]. Can cause hemolytic uremic syndrome, delayed bronchospasm, tracheal / laryngeal stenosis.



[Monoclonal Ab]

Disinhibit T cell breaks - [immune check point \ominus].

- Nivolumab - Hodgkin's lymphoma, Non small cell lung ca, metastatic melanoma.
- PD1 \ominus → Pembrolizumab - Metastatic melanoma, TNF cancers, urothelial cancers, colonic ca, non small cell lung cancer
- PD1 \ominus → Complimab - SCC of skin.
- Avelumab - Merkel cell cancer
- PDL1 \ominus → Durvalumab - urothelial cancers
- Atezolizumab - urothelial cancers, Non small cell lung cancer.
- CTLA4 \ominus → Ipilimumab - Malignant melanoma.

Monoclonal Ab against CD Ag:

- | | |
|---|--|
| Blinatumomab - CD3/19. Philadelphia \ominus ALL | moxetumomab - CD22. Hairy cell leukemia |
| Ofatumomab - CD20. CLL | Brentuximab - CD30 HL, T cell lymphoma |
| Tositumomab - CD20. B cell lymphomas | Gemtuzumab - CD33. CD33 \oplus AML |
| Ibrutinomab - CD20. B cell lymphomas | Daratumumab - CD38. Multiple myeloma |
| Obintuzumab - CD20. B cell NHL, CLL | Alemtuzumab - CD2. CLL, low lymphoma |
| Inotuzumab - CD22. B cell ALL | Emapotuzumab - CD24. HER2+ lymphohistiocytosis |

Rituximab - CD 20 monoclonal Ab

Re - Rheumatoid arthritis

L - Lupus [Systemic lupus erythematosus]

I - Immune thrombocytopenic purpura [ITP]

A - Autoimmune hemolytic anemia

N - Non Hodgkin's lymphoma

Ce - CLL

Monoclonal Ab against growth factor receptors:

EGFR → Cetuximab - colorectal CA, HNF cancers → Rash, hypomagnesemia & hypersensitivity

EGFR → Panitumumab - colorectal CA

Necitumumab - Non small cell lung cancer → cardiotoxicity

Her2/NEU → Trastuzumab - Breast CA, Adeno CA gastroesophageal junction.

Pertuzumab - Breast CA.

Ramucirumab - VEGFR2. Non small cell lung CA, gastroesophageal junction cancer.

Beravizumab - VEGF. Colorectal CA, RCC, brain tumor, ovarian CA, non small cell lung CA

Olaratumab - PDGFR α . Soft tissue sarcoma. → HTN, thromboembolism, wound healing complication, GI perforation

Denosumab - RANKL. Giant cell tumor of bone

Dinutuximab - Glycolipid GD2. Neuroblastoma.

Elotuzumab - SLAM. F7. Multiple myeloma

Mogamulizumab - CCR4. Mycosis fungoides & sezary syndrome.

Tyrosine kinase Θ

cML → B - Bosutinib [resistant case]

cML → I - Imatinib [DOC]

N - Nilotinib

D - Dasatinib

Proteins - Ponatinib


NSCLC → O - Osimertinib

NSCLC → A - Afatinib, Alemtuzumab

NSCLC → E - Entrectinib → Rash, diarrhoea, anorexia, fatigue.

NSCLC → C - Crizotinib, ceritinib

G - Gefitinib



BY STUDENTS FOR STUDENTS

RCC
 P - Pazopanib
 A - Axitinib
 S -索拉非尼
 S - Sunitinib

malignant melanoma
 C - Cobimetinib
 D - Dabrafenib
 V - Vemurafenib
 T - Trametinib

GIST
 S - Sunitinib
 I - Imatinib
 R - Regorafenib

Proteasome ⊖

Bortezomib, carfilzomib, ixazomib → ⊖ proteasomes → Downregulate NFκB → ↓ cell survival. Used for resistant multiple myeloma.

Histone deacetylase ⊖

Vorinostat, Romidepsin → cutaneous T cell lymphoma

Panobinostat → Multiple myeloma

Belinostat → Relapsed / Refractory peripheral T cell lymphoma

mTOR ⊖

Everolimus, temsirolimus prodrugs → sirolimus → ⊖ mTOR.

Everolimus - breast, pancreatic, brain & renal cell carcinoma] AJW interstitial lung disease

Temsirolimus - Advanced renal cell carcinoma

PARP ⊖

Olaparib, rucaparib - Oral treatment of ovarian cancer

Niraparib - ovarian, fallopian tubes or 1^o peritoneal cancers.

Talazoparib - Advanced breast cancers \geq BRCA mutations

CDK ⊖ Palbociclib, abemaciclib, ribociclib → ⊖ CDK 4/6. Post menopausal ER+, her2- breast cancer patients

PI3 kinase ⊖ Idelalisib - relapsing cl. follicular B cell NHL & SLH.

Copanlisib - follicular lymphoma → dual $\gamma + \delta$ ⊖

Duvetisib - cl & follicular lymphoma

Hedgehog pathway \ominus Sonidegib, vismodegib - Basal cell carcinoma.

Glasdegib - only hedgehog pathway \ominus used for AML.

BCL2 \ominus Venetoclax \ominus BCL2 \rightarrow \oplus apoptosis. CLL.

IDH2 \ominus Enasidenib, Ivosidenib \rightarrow \ominus Isocitrate dehydrogenase 2 \rightarrow AML



FitDocMed
BY STUDENTS FOR STUDENTS

Join FitDocMed Courses at
www.fitdocmed.com